KRAS and non-small cell lung carcinoma: This observation is of interest given that concurrent KRAS/STK11 and KRAS/KEAP1 comutations have been shown to be associated with resistance to ICI in NSCLC.24,25 Comutation patterns in high and low TMB cases among squamous cancers are shown in eFigure 27 in the Supplement.